2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Annals Of Internal Medicine 2022, 175: 1221-1229. PMID: 35939812, DOI: 10.7326/m21-4119.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyLong-term extension studyHCV reinfectionDrug useExtension studyAgonist therapySuccessful treatmentHepatitis C virus (HCV) reinfectionHepatitis C virus infectionBenefits of cureC virus infectionChronic HCV infectionRate of reinfectionUrine drug screeningOngoing drug useClinical trial sitesSubsidiary of MerckHCV infectionCohort studyVirus reinfectionDohme Corp.Treatment completionGenotype 1Virus infectionHigh risk
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individualsBuprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 2006, 43: s169-s172. PMID: 17109302, DOI: 10.1086/508179.BooksMeSH KeywordsAntiretroviral Therapy, Highly ActiveBuprenorphineDelivery of Health Care, IntegratedFemaleFollow-Up StudiesHealth Services ResearchHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersPrimary Health CarePrimary PreventionRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesConceptsHuman immunodeficiency virusDrug abuseCare settingsTreatment of HIVHIV primary care settingPrimary HIV care settingsMental Health Services AdministrationHIV primary careProvision of buprenorphineActive antiretroviral therapyHIV care settingsPrimary care settingCollaborative HIV ResearchHealth Services AdministrationAddiction/dependenceAntiretroviral therapyHIV infectionImmunodeficiency syndromeImmunodeficiency virusPrimary careSuccessful treatmentDrug abusersHIV researchDisease controlSubstance abuse